Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration
(RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical
trial that investigates the effect of fixed monthly intravitreal injections of ranibizumab
(Lucentis, Novartis Pharma, Germany) on visual acuity and retinal morphology over a study
period of 12 months in 30 patients.